Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Pathological transition as the arising mechanism for drug resistance in lung cancer.

Chen Y, Tang WY, Tong X, Ji H.

Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8. Review.

2.

There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.

Clery E, Pisapia P, Feliciano S, Vigliar E, Marano A, De Luca C, Malapelle U, Troncone G, Bellevicine C.

J Clin Pathol. 2017 Sep;70(9):798-802. doi: 10.1136/jclinpath-2017-204370. Epub 2017 Mar 31.

PMID:
28363898
3.

Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.

Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, Ju RJ, Li XY, Zhao WY, Lu WL.

Biomaterials. 2013 Apr;34(13):3366-80. doi: 10.1016/j.biomaterials.2013.01.055. Epub 2013 Feb 11.

PMID:
23410681

Supplemental Content

Loading ...
Support Center